Free Trial

Medtronic (MDT) Stock Forecast & Price Target

Medtronic logo
$87.25 +1.23 (+1.43%)
As of 03:58 PM Eastern

Medtronic - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
9
Buy
10

Based on 19 Wall Street analysts who have issued ratings for Medtronic in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 19 analysts, 9 have given a hold rating, 8 have given a buy rating, and 2 have given a strong buy rating for MDT.

Consensus Price Target

$97.87
12.17% Upside
According to the 19 analysts' twelve-month price targets for Medtronic, the average price target is $97.87. The highest price target for MDT is $110.00, while the lowest price target for MDT is $87.00. The average price target represents a forecasted upside of 12.17% from the current price of $87.25.
Get the Latest News and Ratings for MDT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Medtronic and its competitors.

Sign Up

MDT Analyst Ratings Over Time

TypeCurrent Forecast
6/30/24 to 6/30/25
1 Month Ago
5/31/24 to 5/31/25
3 Months Ago
4/1/24 to 4/1/25
1 Year Ago
7/1/23 to 6/30/24
Strong Buy
2 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
5 Buy rating(s)
Hold
9 Hold rating(s)
8 Hold rating(s)
8 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$97.87$97.00$96.07$93.00
Forecasted Upside12.17% Upside16.83% Upside8.57% Upside18.16% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Hold
Hold

MDT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MDT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Medtronic Stock vs. The Competition

TypeMedtronicMedical CompaniesS&P 500
Consensus Rating Score
2.63
2.81
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside12.69% Upside8,873.84% Upside12.50% Upside
News Sentiment Rating
Positive News

See Recent MDT News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/30/2025Wolfe Research
4 of 5 stars
Mike Polark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Peer Perform
6/16/2025Leerink Partnrs
1 of 5 stars
M. Kratky
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/16/2025Leerink Partners
1 of 5 stars
Mike Kratky
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$110.00+26.16%
6/6/2025Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Mike Matson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/22/2025Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Anthony Petrone
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$100.00 ➝ $98.00+19.99%
5/22/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Shagun Singh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$105.00 ➝ $101.00+24.10%
5/22/2025Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Rescott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$94.00 ➝ $92.00+12.71%
4/11/2025Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Richard Newitter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetHold ➝ Hold$93.00 ➝ $90.00+10.25%
3/4/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Joanne Wuensch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$92.00 ➝ $107.00+13.59%
2/19/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Danielle Antalffy
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral ➝ Neutral$85.00 ➝ $95.00+10.40%
11/26/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$105.00 ➝ $109.00+27.11%
11/20/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$96.00 ➝ $97.00+15.68%
11/20/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$106.00 ➝ $98.00+13.95%
11/15/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$99.00 ➝ $96.00+9.84%
10/1/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$100.00 ➝ $104.00+16.16%
8/23/2024Daiwa America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Department
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/21/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$85.00 ➝ $90.00+4.41%
8/21/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$85.00 ➝ $87.00+1.90%
8/21/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform ➝ Market Perform$92.00 ➝ $94.00+10.10%
5/30/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSell$83.00+1.84%
11/22/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$104.00 ➝ $98.00+24.68%
6/30/202322nd Century Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingInitiates
6/30/2023CL King
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$106.00+22.16%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 05:57 PM ET.


Should I Buy Medtronic Stock? MDT Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, June 28, 2025. Please send any questions or comments about these Medtronic pros and cons to contact@marketbeat.com.

Medtronic
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Medtronic plc:

  • The current stock price is around $86.19, which is near its 12-month high, indicating strong market performance and investor confidence.
  • Medtronic plc recently reported earnings that exceeded analysts' expectations, showcasing its ability to generate revenue and profit effectively.
  • The company has a solid dividend yield of 3.29%, which can provide a steady income stream for investors.
  • With a debt-to-equity ratio of 0.53, Medtronic plc maintains a healthy balance sheet, suggesting lower financial risk compared to companies with higher debt levels.
  • Analysts have a consensus rating of "Moderate Buy" for Medtronic plc, with several upgrades indicating positive sentiment about its future performance.

Medtronic
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Medtronic plc for these reasons:

  • Despite recent earnings growth, the company's revenue increase of 3.9% year-over-year may not be sufficient to meet higher investor expectations.
  • The payout ratio of 77.35% indicates that a significant portion of earnings is being distributed as dividends, which could limit funds available for reinvestment in growth opportunities.
  • Recent price target reductions by analysts suggest that there may be concerns about the company's future growth potential.
  • With a P/E ratio of 23.81, the stock may be considered overvalued compared to industry peers, which could deter value-focused investors.
  • Market volatility and economic uncertainties could impact Medtronic plc's performance, making it a riskier investment in the current climate.

MDT Forecast - Frequently Asked Questions

According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Medtronic is $97.87, with a high forecast of $110.00 and a low forecast of $87.00.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medtronic in the last twelve months. There are currently 9 hold ratings, 8 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MDT shares.

According to analysts, Medtronic's stock has a predicted upside of 12.17% based on their 12-month stock forecasts.

Over the previous 90 days, Medtronic's stock had 2 upgrades by analysts.

Medtronic has been rated by research analysts at Leerink Partners, Leerink Partnrs, Mizuho, Needham & Company LLC, Robert W. Baird, Royal Bank Of Canada, Truist Financial, and Wolfe Research in the past 90 days.

Analysts like Medtronic less than other "medical" companies. The consensus rating score for Medtronic is 2.63 while the average consensus rating score for "medical" companies is 2.81. Learn more on how MDT compares to other companies.


This page (NYSE:MDT) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners